BPC-157 reversed doxorubicin-induced congestive heart failure and reduced the associated Big Endothelin-1 elevation in rats, demonstrating cardioprotective effects against chemotherapy-induced cardiac damage.
Key findingBPC-157 reversed doxorubicin-induced CHF signs and normalized elevated Big Endothelin-1 levels in rats, comparable to amlodipine and losartan — demons
What the researchers found
BPC-157 reversed doxorubicin-induced CHF signs and normalized elevated Big Endothelin-1 levels in rats, comparable to amlodipine and losartan — demonstrating cardioprotective peptide activity against chemotherapy-induced cardiomyopathy.
Why it matters
Relevant for bpc-157, cardiovascular, inflammation.
How the study worked
animal-study study on bpc-157, cardiovascular.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.
Journal of pharmacological sciences, 95(1), 19-26
Citation
Lovric-Bencic, Martina; Sikiric, Predrag; Hanzevacki, Jadranka S; Seiwerth, Sven; Rogic, Dunja; Kusec, Vesna; Aralica, Gorana; Konjevoda, Pasko; Batelja, Lovorka; Blagaic, Alenka B. (2004). Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse.. Journal of pharmacological sciences, 95(1), 19-26.